Infinity Clinical Research

06/24/2024

Thinking about participating in a clinical trial? Click the link below to learn more about our current studies.

https://connect.studycatalyst.com/ #/listings/987519b5-1b2a-42df-a413-cffac398246b/iframe

05/07/2024

The PROGRESS study is being done to find out the efficacy of an investigational drug called LX9211 in reducing pain related to diabetic peripheral neuropathy.

LX9211 is a new type of investigational drug called an AP2-associated protein kinase 1 inhibitor (AAK1 inhibitor). It is believed that inhibiting AAK1 may help reduce pain caused by diabetic neuropathy.

You may qualify to participate if you:
• Are 18 years of age or older
• Have type 1 or type 2 diabetes
• Have an A1C less than or equal to 11%
• Have ongoing diabetic peripheral neuropathy with moderate to severe pain

Your medical history and other criteria will be checked to see if you can take part in the study.

The study lasts about 16 weeks. Qualified participants will not have to pay for the study drug, study visits, or for the procedures or tests that are needed as part of this study. Additionally, you may be compensated for your time and reimbursed for approved, study-related travel.

For info please contact:
Becky Nembhard, BS, CRC
Lead Clinical Research Coordinator
rnembhard@infinityclinicalresearch.com
954-366-0277, ext 124

Working to Advance Progressive Treatments for Patients Through Clinical Trials

04/03/2024

Are you caring for someone with, or who may have, Alzheimer’s disease? Are they showing signs of restlessness, aggression, or irritability?

Researchers who are working on the ADVANCE-2 study are examining if an investigational medication may work to help these symptoms. At this time, there is no approved treatment for restlessness, aggression, or irritability associated with Alzheimer’s disease.

Who can participate in the study?

To be considered for this study, your family member must:
- Be between the ages of 65 and 90 years old
- Have been diagnosed with Alzheimer’s disease, or is showing symptoms of Alzheimer’s
- Be currently showing signs of restlessness, aggression, or irritability

The caregiver must:
- Be a family member who has been caring for the person on a regular basis
- Be willing to attend study visits
- Complete documents on behalf of your family member

*please note other criteria may apply

For more info please contact:
Muskaan Ochani, BS, CRC – 954.366.0277 ext 122
Lucy Vargas, MA, CRC – 954.366.0277 ext 124

06/03/2023

We have spaces open in this study. If you, or someone you know, would like more info please contact our trial coordinator:
Jorge Riveros
954-475-8171, x.120 or jriveros@infinityclinicalresearch.com

Do you have Mild Cognitive Impairment due to AD or mild AD dementia? If yes, and you are ages 60-85, you may be able to participate in a clinical study called ENVISION.

• Study treatment & health assessments provided at no cost
• You may be reimbursed for travel expenses
• You do not need to have health insurance to participate

02/15/2023

If you care for someone who may have a diagnosis of Alzheimer’s disease and they have been experiencing symptoms of disruptive behavior which have made caring for them even more difficult, the ADVANCE-2 study may be an option. This local Alzheimer’s disease research study is seeking people who are:
• Aged 65 to 90 years old
• May have a diagnosis of Alzheimer’s disease
• Currently exhibiting or showing signs of restlessness, aggression or irritability
• Have a dedicated caregiver
(Additional eligibility criteria apply)

If you think your family member may qualify, please contact us for more information. Call 954-475-8171 and speak with Maria at extenstion 146 or Muskaan at extension 134.

Qualified participants will receive study-related care at no cost, and their overall health will be closely monitored by a study doctor. They may also be paid for their time and reimbursed for travel-related expenses.

01/23/2023

Do you, or someone you know, have Mild Cognitive Impairment due to AD or mild AD dementia? If yes, and you are ages 60-85, you may be able to participate in a clinical study called ENVISION.
• Study treatment & health assessments provided at no cost
• You may be reimbursed for travel expenses
• You do not need to have health insurance to participate

For more info, please contact our trial coordinator Jorge Riveros:
954-475-8171, x.120 • jriveros@infinityclinicalresearch.com

09/02/2021

If you have MS and have not yet received the flu shot, we'd like to speak with you about this clinical trial. Please call 954-475-8171, ext 134.

08/26/2021

If you are being treated for MS but have not yet received the COVID-19 vaccine, we'd like to speak with you about a new research study evaluating the immune response in MS patients after receiving the vaccine. Please call Michele Fistel at 954.475.8171, ext 143 or email mfistel@infinityclinicalresearch.com.

08/05/2021

We're conducting a clinical trial for people who are affected by migraines. For more information, please call 954-620-3340, ext 121.

Working to Advance Progressive Treatments for Patients Through Clinical Trials

06/08/2021

We are so proud to have participated in the clinical trials (Emerge and Embark at our Hollywood office) that ultimately led to this drug being approved for the treatment of Alzheimer's disease!

The FDA approved a drug for the treatment of Alzheimer’s Disease

02/22/2021

Are you taking Gilenya or Tecfidera? Have you had a relapse in the last year? If YES we have a new research study for you.

The Artios Study: A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab study treatment effectiveness and participant-reported outcomes in people with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy. For ages 18-60.

For info, please call Michele at Infinity Clinical Research: 954-475-8171, x.134.